ControlRad announced today that it received FDA 510(k) clearance to market its ControlRad Select radiation reduction technology.
Atlanta-based ControlRad’s technology uses proprietary semi-transparent filters with a user-interface tablet and imaging processing algorithms that are retrofitted onto customers’ existing Siemens Artis zee interventional imaging systems, according to a news release.
ControlRad, ahead of its commercialization efforts for the platform, also entered into an exclusive agreement with Boston Scientific (NYSE:BSX) to sell the ControlRad Select technology.
“With the FDA clearance and the reach of the global medical device sales team, every cath, EP, and IR lab in the country that has a Siemens Artis zee will now have the opportunity to reduce their radiation dose by 85% without compromising image quality,” ControlRad CEO Guillaume Bailliard said in the release.